The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy<SUBTITLE>A Randomized Trial</SUBTITLE>
Abstract
CONTEXT: Peripheral lipoatrophy may complicate antiretroviral therapy of human immunodeficiency virus (HIV) infection, often related to duration and type of nucleoside analog therapy, and may have a mitochondrial pathogenesis. No proven therapy exists for lipoatrophy, but abacavir is a nucleoside analog that may be less toxic to mitochondria. OBJECTIVE: To determine if substitution of stavudine or zidovudine with abacavir improves HIV lipoatrophy without affecting control of HIV replication. DESIGN: Randomized, open-label 24-week study. SETTING: Seventeen hospital HIV outpatient clinics and primary care centers in Australia and England, with randomization from June 2000 through January 2001. PARTICIPANTS: A total of 111 adults (109 men) with moderate or severe lipoatrophy who were receiving stavudine (n = 85) or zidovudine (n = 26) and had stable plasma HIV RNA levels below 400 copies/mL and no prior abacavir therapy. INTERVENTION: Patients were randomly assigned to switch from stavudine or zidovudine to abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n = 54) or to continue all antiretroviral therapy (n = 57). MAIN OUTCOME MEASURES: The primary end point was limb fat mass, measured by dual-energy x-ray absorptiometry; key secondary end points were plasma HIV RNA levels, adverse events, physician-assessed (via subjective measures) lipodystrophy severity, total and central fat mass, and fasting metabolic (lipid, glycemic, and lactate) levels. RESULTS: There was a significant increase in limb fat in the abacavir group relative to the stavudine/zidovudine group (0.39 vs 0.08 kg; mean difference, 0.31; 95% confidence interval [CI], 0.06-0.57 kg), as well as significant relative increases in subcutaneous thigh (P =.01), arm (P<.001), and abdominal (P =.001) fat areas on computed tomography. Switching had no significant effect on secondary end points, including plasma HIV RNA (for unadjusted comparison between groups at week 24, odds ratio, 1.38; 95% CI, 0.48-3.96). Change in limb fat mass at week 24 did not correlate with change in subjectively determined perceived lipoatrophy severity (r = -0.06; P =.53 by Spearman correlation). Hypersensitivity to abacavir was seen in 5 patients (10%). CONCLUSIONS: In this sample of lipoatrophic HIV-infected adults, switching from stavudine or zidovudine to abacavir for 24 weeks led to significant, albeit modest, objectively measured increases in limb fat. Clinical lipoatrophy, as assessed subjectively, did not resolve, however, and at the rate of increase observed may take years to resolve with use of this strategy. Longer-term follow-up is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Self-citationCarr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Self-citationAdverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Self-citationVisceral abdominal-fat accumulation associated with use of indinavir
Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I., & Falloon, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11518-5 · Cited by 700
Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J.-M., Gastaut, J.-A., & Touraine, J.-L. (1999) · AIDS · doi:10.1097/00002030-199909100-00009 · Cited by 581
“Buffalo hump” in men with HIV-1 infection
Lo, J. C., Mulligan, K., Tai, V. W., Algren, H., & Schambelan, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11443-x · Cited by 567
Mallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000) · AIDS · doi:10.1097/00002030-200007070-00002 · Cited by 510
Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
Lichtenstein, K. A., Ward, D. J., Moorman, A. C., Delaney, K. M., Young, B., Palella, F. J., Rhodes, P. H., Wood, K. C., & Holmberg, S. D. (2001) · AIDS · doi:10.1097/00002030-200107270-00008 · Cited by 427
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
Cited by
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., Glesby, M. J., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 580
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study
Carr, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12656-6 · Cited by 422
Self-citationSchambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dubé, M. P., Gerber, J. G., Grinspoon, S. K., Grunfeld, C., Kotler, D. P., Mulligan, K., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200211010-00001 · Cited by 379
Self-citationValantin, M.-A., Aubron-Olivier, C., Ghosn, J., Laglenne, E., Pauchard, M., Schoen, H., Bousquet, R., Katz, P., Costagliola, D., & Katlama, C. (2003) · AIDS · doi:10.1097/00002030-200311210-00009 · Cited by 355
Moyle, G. J., Sabin, C. A., Cartledge, J., Johnson, M., Wilkins, E., Churchill, D., Hay, P., Fakoya, A., Murphy, M., Scullard, G., et al. (2006) · AIDS · doi:10.1097/01.aids.0000247574.33998.03 · Cited by 273
Metadata
- Authors
- Carr, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-10
- Volume
- 288
- Issue
- 2
- Pages
- 207
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2054385676
- Cited by
- 300
- References
- 20
- FWCI
- 40.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy<SUBTITLE>A Randomized Trial</SUBTITLE>. https://app.cochat.ai/papers/10.1001/jama.288.2.207
- The paper
- Carr, A. (2002). Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy<SUBTITLE>A Randomized Trial</SUBTITLE>. JAMA. https://doi.org/10.1001/jama.288.2.207
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.